A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.
In a Reuters roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, common cold antibodies yield clues to Covid-19 behavior.
AstraZeneca’s Brilinta (ticagrelor) was approved by the U.S. Food and Drug Administration to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack.
Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.
A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.
AstraZeneca released positive data from the Phase III THALES trial of Brilinta (ticagrelor) used twice a day with an aspirin.
Britain’s AstraZeneca clinched expanded regulatory backing for two medications, including one for the blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine.
Spring Bank Pharmaceuticals, based in Hopkinton, Massachusetts, is discontinuing development of inarigivir soproxil for chronic hepatitis B virus (HBV).
AstraZeneca announced that the company’s Brilinta (ticagrelor) hit the primary endpoint in the Phase III THALES trial in stroke.
U.S. health regulators approved expanding the heart benefit claims Amarin Corp. can make in promoting the company’s drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.